{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:41:16Z","timestamp":1792802476159,"version":"4.5.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"18","license":[{"start":{"date-parts":[[2017,11,10]],"date-time":"2017-11-10T00:00:00Z","timestamp":1510272000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1007\/s40265-017-0838-6","type":"journal-article","created":{"date-parts":[[2017,11,10]],"date-time":"2017-11-10T05:04:14Z","timestamp":1510290254000},"page":"2057-2062","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":139,"title":["Copanlisib: First Global Approval"],"prefix":"10.1007","volume":"77","author":[{"given":"Anthony","family":"Markham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,10]]},"reference":[{"issue":"11","key":"838_CR1","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1158\/1535-7163.MCT-12-0993-T","volume":"12","author":"N Liu","year":"2013","unstructured":"Liu N, Rowley BR, Bull CO, et al. BAY 80-6946 is a highly selective intravenous pI3K inhibitor with potent p110alpha and p110delta activities in tumor cell lines and xenograft models. Mol Cancer Ther. 2013;12(11):2319\u201330.","journal-title":"Mol Cancer Ther."},{"key":"838_CR2","unstructured":"Bayer. FDA grants Bayer priority review for investigational compound copanlisib in follicular lymphoma [media release]. 17 May 2017."},{"key":"838_CR3","unstructured":"FDA. Aliqopa (Copanlisib) prescribing information. 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209936s000lbl.pdf . Accessed 10 Oct 2017."},{"key":"838_CR4","doi-asserted-by":"crossref","first-page":"e141","DOI":"10.1038\/bcj.2013.37","volume":"3","author":"J Glauer","year":"2013","unstructured":"Glauer J, Pletz N, Schon M, et al. A novel selective small-molecule PI3K inhibitor is effective against human multiple myeloma in vitro and in vivo. Blood Cancer J. 2013;3:e141.","journal-title":"Blood Cancer J."},{"issue":"Suppl 1","key":"838_CR5","first-page":"235","volume":"33","author":"J Paul","year":"2015","unstructured":"Paul J, Wengner AM, Petrova E, et al. Copanlisib attenuates both BCR-dependent and BCR-independent activation of NFKB in DLBCL cells [abstract no. 268]. Hematol Oncol. 2015;33(Suppl 1):235.","journal-title":"Hematol Oncol."},{"issue":"Suppl 1","key":"838_CR6","first-page":"551","volume":"100","author":"A Zoellner","year":"2015","unstructured":"Zoellner A, Arnd J, Hutter G, et al. Efficacy of the pan PI3K-inhibitor copanlisib compared to selective PI3K-a,-b,-delta inhibitors in mantle cell lymphoma (MCL) [abstract no. E1375]. Haematologica. 2015;100(Suppl 1):551.","journal-title":"Haematologica."},{"key":"838_CR7","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1093\/annonc\/mdw282","volume":"27","author":"A Patnaik","year":"2016","unstructured":"Patnaik A, Appleman LJ, Tolcher AW, et al. First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin\u2019s lymphomas. Ann Oncol. 2016;27:1928\u201340.","journal-title":"Ann Oncol."},{"issue":"3","key":"838_CR8","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00280-017-3383-9","volume":"80","author":"M Gerisch","year":"2017","unstructured":"Gerisch M, Schwarz T, Lang D, et al. Pharmacokinetics of intravenous pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor [14C]copanlisib (BAY 80-6946) in a mass balance study in healthy male volunteers. Cancer Chemother Pharmacol. 2017;80(3):535\u201344.","journal-title":"Cancer Chemother Pharmacol."},{"issue":"Suppl 1","key":"838_CR9","first-page":"S55","volume":"99","author":"S Reif","year":"2016","unstructured":"Reif S, Ahsman M, Jentsch G, et al. Use of a population pharmacokinetic approach and time-to-event analysis to support the clinical recommendation of a flat dosing of copanlisib in cancer patients [abstract no. PI-093]. Clin Pharmacol Ther. 2016;99(Suppl 1):S55.","journal-title":"Clin Pharmacol Ther."},{"issue":"Suppl 2","key":"838_CR10","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/hon.2439_187","volume":"35","author":"J Gerecitano","year":"2017","unstructured":"Gerecitano J, Santoro A, Leppa S, et al. Safety run-in of copanlisib in combination with rituximab plus bendamustine in patients with relapsed indolent non-Hodgkin\u2019s lymphoma [abstract no. 477]. Hematol Oncol. 2017;35(Suppl 2):408\u201310.","journal-title":"Hematol Oncol."},{"issue":"9","key":"838_CR11","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1093\/annonc\/mdx289","volume":"28","author":"M Dreyling","year":"2017","unstructured":"Dreyling M, Morschhauser F, Bouabdallah K, et al. Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. Ann Oncol. 2017;28(9):2169\u201378.","journal-title":"Ann Oncol."},{"key":"838_CR12","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.75.4648","author":"M Dreyling","year":"2017","unstructured":"Dreyling M, Santoro A, Mollica L, et al. Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma. J Clin Oncol. 2017. https:\/\/doi.org\/10.1200\/jco.2017.75.4648 .","journal-title":"J Clin Oncol."},{"issue":"Suppl 2","key":"838_CR13","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/hon.2437_56","volume":"35","author":"G Lenz","year":"2017","unstructured":"Lenz G, Hawkes E, Verhoef G, et al. Clinical outcomes and molecular characterization from a phase II study of copanlisib in patients with relapsed or refractory diffuse large B-cell lymphoma [abstract no. 57]. Hematol Oncol. 2017;35(Suppl 2):68\u20139.","journal-title":"Hematol Oncol."},{"key":"838_CR14","doi-asserted-by":"crossref","unstructured":"Ramanathan RK, Von Hoff DD, Eskens F, et al. A phase 1b trial of PI3K inhibitor copanlisib (BAY 80-6946) combined with the allosteric-MEK inhibitor refametinib (BAY 86-9766) in patients with advanced cancer [abstract no. 2588]. J Clin Oncol Conf. 2014;32(Suppl 1).","DOI":"10.1200\/jco.2014.32.15_suppl.2588"},{"key":"838_CR15","doi-asserted-by":"crossref","unstructured":"Kim RD, Alberts SR, Renshaw FG, et al. Phase 1 dose escalation study of copanlisib (BAY 80-6946) in combination with gemcitabine or gemcitabine-cisplatin in advanced cancer patients [abstract no. 2610]. J Clin Oncol Conf. 2014;32(Suppl 1).","DOI":"10.1200\/jco.2014.32.15_suppl.2610"},{"key":"838_CR16","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00280-016-3198-0","volume":"79","author":"T Doi","year":"2017","unstructured":"Doi T, Fuse N, Yoshino T, et al. A phase I study of intravenous PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumors. Cancer Chemother Pharmacol. 2017;79:89\u201398.","journal-title":"Cancer Chemother Pharmacol"},{"key":"838_CR17","doi-asserted-by":"crossref","unstructured":"Nowakowski GS, Gorbatchevsky I, Hiemeyer F, et al. A randomized, double-blind phase III study of phosphatidylinositol 3 kinase alpha\/delta inhibitor copanlisib versus placebo in patients with rituximab refractory indolent non Hodgkin\u2019s lymphoma (iNHL): CHRONOS2 [abstract no. CT084]. Cancer Res. 2016;76(14 Suppl).","DOI":"10.1158\/1538-7445.AM2016-CT084"},{"key":"838_CR18","doi-asserted-by":"crossref","unstructured":"Gerecitano JF, Zinzani PL, Zheng HX, et al. Phase III randomized, double-blind, controlled studies of the PI3K inhibitor copanlisib in combination with rituximab or rituximab-based chemotherapy in subjects with relapsed indolent B-cell non-Hodgkin\u2019s lymphoma (iNHL): CHRONOS-3 and CHRONOS-4 [abstract no. CT085]. Cancer Res. 2016;76(14 Suppl).","DOI":"10.1158\/1538-7445.AM2016-CT085"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-017-0838-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-017-0838-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-017-0838-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,5]],"date-time":"2019-10-05T19:53:41Z","timestamp":1570305221000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-017-0838-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,10]]},"references-count":18,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["838"],"URL":"https:\/\/doi.org\/10.1007\/s40265-017-0838-6","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,10]]}}}